These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Depressed T cell proliferative responses in Hodgkin's disease: role of monocyte-mediated suppression via prostaglandins and hydrogen peroxide. Fisher RI; Bostick-Bruton F J Immunol; 1982 Oct; 129(4):1770-4. PubMed ID: 6980949 [TBL] [Abstract][Full Text] [Related]
3. Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from untreated patients with Hodgkin's disease. Romagnani S; Del Prete GF; Maggi E; Bellesi G; Biti G; Rossi Ferrini PL; Ricci M J Clin Invest; 1983 May; 71(5):1375-82. PubMed ID: 6602150 [TBL] [Abstract][Full Text] [Related]
5. Role of suppressor cells in depression of T lymphocyte proliferative response in untreated and treated Hodgkin's disease. Han T Cancer; 1980 Apr; 45(8):2102-8. PubMed ID: 6445226 [TBL] [Abstract][Full Text] [Related]
6. Splenic T and B lymphocytes and their mitogenic response in untreated Hodgkin's disease. Han T; Minowada J; Subramanian V; Barcos M; Kim U Cancer; 1980 Feb; 45(4):767-74. PubMed ID: 6965606 [TBL] [Abstract][Full Text] [Related]
7. Impaired proliferative response and low interleukin-2 production in patients with lymphoma. Musatti CC; Yasaka K; Santos LM Braz J Med Biol Res; 1987; 20(3-4):351-62. PubMed ID: 3502537 [TBL] [Abstract][Full Text] [Related]
8. B lymphocytes in untreated patients with malignant lymphoma and Hodgkin's disease. Gajl-Peczalska KJ; Hansen JA; Bloomfield CD; Good RA J Clin Invest; 1973 Dec; 52(12):3064-73. PubMed ID: 4201499 [TBL] [Abstract][Full Text] [Related]
9. Neoplastic cells obtained from Hodgkin's disease function as accessory cells for mitogen-induced human T cell proliferative responses. Fisher RI; Bates SE; Bostick-Bruton F; Tuteja N; Diehl V J Immunol; 1984 May; 132(5):2672-7. PubMed ID: 6609204 [TBL] [Abstract][Full Text] [Related]
10. Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease. Schulof RS; Bockman RS; Garofalo JA; Cirrincione C; Cunningham-Rundles S; Fernandes G; Day NK; Pinsky CM; Incefy GS; Thaler HT; Good RA; Gupta S Cancer; 1981 Aug; 48(4):964-73. PubMed ID: 6456060 [TBL] [Abstract][Full Text] [Related]
11. Impaired T- and B-cell functions in patients with Hodgkin's disease. Reduced mitogenic responsibility and Il-2 production is not caused by defective CD4+-cells. Bergmann L; Mitrou PS; Demmer-Dieckmann M; Ruhmann FT; Weidmann E Cancer Immunol Immunother; 1987; 25(1):59-64. PubMed ID: 3496158 [TBL] [Abstract][Full Text] [Related]
12. Lymphocyte abnormalities in untreated patients with Hodgkin's disease. Holm G; Mellstedt H; Björkholm M; Johansson B; Killander D; Sundblad R; Söderberg G Cancer; 1976 Feb; 37(2):751-62. PubMed ID: 1082795 [TBL] [Abstract][Full Text] [Related]
13. Distinguishing features of the immunology of Hodgkin's disease in children. Tan CT; De Sousa M; Good RA Cancer Treat Rep; 1982 Apr; 66(4):969-75. PubMed ID: 7074657 [TBL] [Abstract][Full Text] [Related]
14. Quantitative and functional abnormalities of total T lymphocytes in relatives of patients with Hodgkin's disease. del Giacco GS; Cengiarotti L; Mantovani G; Murgia M; Broccia G; Corda G; di Tucci A Eur J Cancer Clin Oncol; 1985 Jul; 21(7):793-801. PubMed ID: 3876218 [TBL] [Abstract][Full Text] [Related]
15. Functional activities of enriched Fc receptor bearing T lymphocytes in Hodgkin's disease. Gulwani BN; Advani SH; Gangal SG Oncology; 1986; 43(3):159-64. PubMed ID: 2939383 [TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease. Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978 [TBL] [Abstract][Full Text] [Related]
17. Expression and signal transduction of T-cell antigen receptor (TCR)/CD3 complexes on fresh or in vitro expanded T lymphocytes from patients with Hodgkin's and non-Hodgkin's lymphomas. Rubin B; Martin EP; Arnaud J; Delsol G; Plesner T; Ratsimbazafy A; Llobera R; Holm B; Mariame B Scand J Immunol; 1997 Jun; 45(6):715-25. PubMed ID: 9201313 [TBL] [Abstract][Full Text] [Related]
18. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Stein H; Mason DY; Gerdes J; O'Connor N; Wainscoat J; Pallesen G; Gatter K; Falini B; Delsol G; Lemke H Blood; 1985 Oct; 66(4):848-58. PubMed ID: 3876124 [TBL] [Abstract][Full Text] [Related]
19. Impaired autologous mixed lymphocyte reactivity in Hodgkin's disease. Begemann M; Claas G; Falke H Klin Wochenschr; 1982 Jan; 60(1):19-26. PubMed ID: 6210797 [TBL] [Abstract][Full Text] [Related]
20. Evidence for the involvement of monocyte-derived toxic oxygen metabolites in the lymphocyte dysfunction of Hodgkin's disease. Deshazo RD; Ewel C; Londono S; Metzger Z; Hoffeld JT; Oppenheim JJ Clin Exp Immunol; 1981 Nov; 46(2):313-20. PubMed ID: 7337972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]